Apollo Therapeutics, a biopharmaceutical company originally set up by three UK universities (Cambridge, Imperial College London and University College London) and three pharmaceutical companies (AstraZeneca, GSK and Johnson & Johnson Innovation), has secured $226.5 million venture capital financing.
Cambridge's Experimental Medicine Initiative, working with AstraZeneca and GSK, is training specialists who can work out at an earlier stage of clinical trials if a treatment is likely to succeed.
Operations Director Karl Wilson has helped lead a herculean effort to transform a standard laboratory into a bespoke testing centre, to aid the national response against COVID-19. For him, there was never any question about whether we should - or could - do this.
As part of the UK Government’s announcement of a new five pillar plan to boost testing for COVID-19, AstraZeneca, GSK and the University of Cambridge have formed a joint collaboration to take action to support this national effort.